Cannabis stocks soar, then dive, while grass becomes legal in Canada


[ad_1]

The shares of Canadian Cannabis Growth (CGC), Cronos (CRON) and Tilray (TLRY) – which are trading in the United States – have skyrocketed over the past week – and all the year in fact .

But they were all extremely volatile and plunged on Wednesday as well, a classic case of investors buying the rumor and selling the news.

The shares of two other Canadian companies – Aurora Cannabis (ACBFF) and Aphria (APHQF) – also took a rollercoaster ride, mainly because of the speculation that large consumer products companies may seek to invest in them.
Coca-Cola (KO) examined Aurora and the Marlboro manufacturer, Altria (MO) examined Aphria.
Rumors have a meaning. The beer and wine giant, Constellation Brands (STZ), has already agreed to take a more than $ 4 billion stake in Canopy. Some believe that large pharmaceutical companies might want to invest in cannabis companies.

"Moment" for marijuana

Michael Gorenstein, CEO of Cronos, would not comment when CNN's Julia Chatterley, on the First Move broadcast on Wednesday, asked if Cronos was looking to partner with a larger company.

But he said legalization in Canada is a "watershed moment" for the industry and he expects the legalization of marijuana to be of greater interest.

"It makes so much sense, it sends a blow, and we are seeing winds that are contrary to regulation around the world," Gorenstein said.

Nick Kovacevich, CEO of KushCo Holdings (KSHB), which manufactures packaging and marketing materials for marijuana companies, told CNN Business that there is considerable potential in the United States.

"Things are moving faster than many people think," said Kovacevich, noting that several polls showed Democrats could take control of the House in the upcoming mid-term elections.

If this happens, Kovacevich thinks that there could be more progress in amending federal cannabis laws.

Others think that the hype becomes exaggerated.

Andrew Left, founder of Citron Research, also appeared on CNN's First Move broadcast Wednesday and said he was betting against many cannabis stocks because he thought marijuana would not not a multibillion dollar industry that many are waiting for.

"There is a huge difference between being excited about an idea and being able to invest in it," said Left. "Yes, cannabis will bring in money, but it's not the technological boom, it's a much smaller pie."

Ken Mahoney, the CEO of Mahoney Asset Management, agreed. He compared the marijuana craze to what happened with the dot-com stock in the late 1990s. That did not end well for a lot of speculative stocks that are trying to hang on to the internet wave.

But Mahoney said finding more easily what is known as "picks and shovels" in the industry – companies that take advantage of the cannabis trend but are not producers – makes more sense.

"It's crazy to choose individual companies selling marijuana, so do not rely on companies that can benefit from the general trend of legal cannabis but have diversification," he said. Mahoney likes KushCo, for example.

He is also optimistic for fertilizer giant Scotts Miracle-Gro (SMG), who recently acquired Sunlight Supply, a leading manufacturer of hydroponic products that help people grow cannabis indoors.
Mahoney also likes GW Pharmaceuticals (GWPH) – which owns an FDA-approved cannabis-based drug for treating certain forms of epilepsy – and Innovative Industrial Properties (IIPR), a real estate company that rents properties to growers. cannabis for medical purposes.

Beware of the "green rush"

Paul Rosen, co-founder of Cronos and today CEO of Tidal Royalty, a company that invests in cannabis companies based in the United States, agreed that there would be good investment opportunities.

But he told CNN Business that investors needed to look carefully at the balance sheets of cannabis companies.

Rosen said that the cannabis cultivation industry requires a lot of capital and that the so-called "green fever" of arousal about marijuana stocks has led to extremely high and unsustainable valuations. Some businesses will inevitably collapse and burn.

He joked that all businesses can not become the Google of cannabis. Some will be Ask Jeeves.

Brady Cobb, CEO of Scythian Biosciences (SCCYF), a Canadian medical cannabis company specializing in the treatment of concussions and other traumatic brain injuries, challenged the comparison with the madness of Internet actions.
Cobb told CNN Business that the company plans to open several marijuana clinics for medical purposes in Florida in early 2019.

"We're actually selling a product that people want to buy, it's not selling domain names," Cobb said.

[ad_2]Source link